Compare · ELOX vs ZYME
ELOX vs ZYME
Side-by-side comparison of Eloxx Pharmaceuticals Inc. (ELOX) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while ZYME focuses on Biotechnology: Pharmaceutical Preparations.
- ZYME is the larger of the two at $393.4M, about 7.1x ELOX ($55.3M).
- Over the past year, ELOX is up 25.6% and ZYME is up 36.2% - ZYME leads by 10.6 points.
- ZYME has been more active in the news (7 items in the past 4 weeks vs 2 for ELOX).
- ZYME has more recent analyst coverage (25 ratings vs 7 for ELOX).
- Company
- Eloxx Pharmaceuticals Inc.
- Zymeworks Inc.
- Price
- $12.88-3.56%
- $25.03-2.95%
- Market cap
- $55.3M
- $393.4M
- 1M return
- -27.89%
- -9.01%
- 1Y return
- +25.61%
- +36.18%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 7
- Recent ratings
- 7
- 25
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Latest ELOX
- Cantor Fitzgerald initiated coverage on Eloxx Pharmaceuticals
- SEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.
- Leerink Partners initiated coverage on Eloxx Pharmaceuticals with a new price target
- SEC Form S-1 filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
- Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Eloxx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.
- Guggenheim initiated coverage on Eloxx Pharmaceuticals with a new price target
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)
Latest ZYME
- SEC Form PRE 14A filed by Zymeworks Inc.
- Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
- SEC Form 4 filed by Zymeworks Inc.
- TD Cowen initiated coverage on Zymeworks with a new price target
- Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
- Zymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Zymeworks Completes Acquisition of Theravance Biopharma
- Wolfe Research initiated coverage on Zymeworks
- H.C. Wainwright reiterated coverage on Zymeworks with a new price target
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits